

<b>INFORMATION DISCLOSURE CITATION</b>	ATTY. DOCKET NO.  <u>47-216</u> APPLICANT	SERIAL NO.  <u>10/517,256</u>
<b>GRAHAM et al</b>		<b>GROUP</b>
(Use several sheets if necessary)		<b>FILED DATE</b>
		<u>January 14, 2005</u>
		<b>1643</b>

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PRIORITY DOCUMENTS						TRANSLATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 98/05349 A1	02/1998	WO				
	WO 96/40657 A1	12/1996	WO				
	WO 02/38575 A1	05/2002	WO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)	
Supplementary European Search Report; European Application No. 03724673.3 – 1223 / 1551803 PCT/AU03/00719; dated 02 July 2009 (7 pgs).	
Ono, T., et al; "Characterization of a novel inhibitor of cytosolic phospholipase A <sub>2</sub> α, pyrrophone"; <i>Biochem, J.</i> ; Vol. 363; pp. 727-735 (2002) (XP-002532197).	
Sved, P., et al; "Oncogenic Action of Secreted Phospholipase A <sub>2</sub> in Prostate Cancer"; <i>Cancer Research</i> ; Vol. 64; pp. 6934-6940 (2004) (XP-002532198).	

*Examiner	/Stephen Rawlings/	Date Considered	10/22/2009
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial a copy of this form with next communication to applicant.			
<b>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /S/</b>			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUOUGH. /SB/